A plasma-based 4-biomarker panel by Bartak et al. [41] including methylated PRIMA1, SDC2, SFRP1, and SFRP2, achieved an excellent overall CRC sensitivity and specificity of 91.5% (43/47) and 97.3% (36/37), along with a promising APL sensitivity of 89.2% (33/37). This evidence concerns the gene SFRP1 and colorectal carcinoma.